Oslo, Norway, December 3, 2021 - The following primary insiders/primary insider’s related parties have today bought a total of 282,000 shares in Nykode Therapeutics (formerly Vaccibody*) at NOK 74.60 per share:

Datum AS                                  94,000
RASMUSSENGRUPPEN AS                       94,000
Caaby AS                                   9,400
Victoria India Fund AS (Andenaesgruppen)  84,600
Total                                    282,000
 
Following the above transactions Jan Haudemann Andersen (board member) and the Datum Group holds 40,357,050 shares (including 11,728,250 shares through Datum AS), Rasmussen Group of companies holds 34,030,750 shares (of which RASMUSSENGRUPPEN AS, in which Trygve Lauvdal (member of the Nykode Therapeutics board) is an employee, owns 28,180,750), Christian Åbyholm (board member) through Caaby AS holds 2,005,295 shares and 100,000 warrants and Andenaesgruppen (through Victoria India Fund AS) represented by Christian Åbyholm owns 17,255,175 shares and in addition Norda ASA represented by Christian Åbyholm owns 7,996,755 shares.
 
In order to cover tax liabilities, primary insider Agnete B. Fredriksen, Chief Innovation & Strategy Officer, has today sold 282,000 shares in Nykode Therapeutics through Viginti AS at NOK 74.60 per share.  Following the sale, Agnete B. Fredriksen holds 48,000 shares through Viginti AS and 3,834,900 warrants.

Please see further details in the attached document.

* Vaccibody AS is changing its name to Nykode Therapeutics AS. The change of name was approved by an EGM held on November 30, 2021.